Augmenting atypical antipsychotic medications with clozapin;Clozapin-augmentation mit atypischen antipsychotika

Nervenarzt

Volumn 76, Issue 9, 2005, Pages 1092-1102

  Zink, M ^a   Dressing, H ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

Antipsychotic; Clozapine; Combination therapy; Schizophrenia; Side effects

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE;

CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; PSYCHOSIS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; CLOZAPINE; DRUG COMBINATIONS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 24744468590     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-005-1887-8     Document Type: Review

References (58)

1. Adesanya A, Pantelis C (2000) Adjunctive risperidone treatment in patients with 'clozapine-resistant schizophrenia'. Aust NZ J Psychiatry 34:533-534
2. Beauchemin MA, Millaud F, Nguyen KA (2002) A case of neuroleptic malignant syndrome with clozapine and risperidone. Can J Psychiatry 47:886
3. Bennett MR (1998) Monoaminergic synapses and schizophrenia: 45 years of neuroleptics. J Psychopharmacol 12:289-304
4. Bergemann N, Kopitz J, Kress KR et al. (2004) Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 14:245-250
5. Buchanan RW (1995) Clozapine: efficacy and safety. Schizophr Bull 21:579-591
6. Buckley P, Miller A, Olsen J et al. (2001) When symptoms persist: clozapine augmentation strategies. Schizophr Bull 27:615-628
7. Caccia S (2000) Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 38:393-414
8. Caley CF, Cooper CK (2002) Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother 36:839-851
9. Chong SA, Remington G (2000) Clozapine augmentation: safety and efficacy. Schizophr Bull 26:421-440
10. Croissant B, Hermann D, Olbrich R (2002) Saving potential of clozapine due to combination with amisulpride. Psychopharmakotherapie 8:128-130
11. de Groot IW, Heck AH, van Harten PN (2001) Addition of risperidone to clozapine therapy in chronically psychotic inpatients. J Clin Psychiatry 62:129-130
12. Glassman A, Bigger JT (2001) Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 158:1774-1782
13. Godleski LS, Sernyak MJ (1996) Agranulocytosis after addition of risperidone to clozapine treatment. Am J Psychiatry 153:735-736
14. Gupta S, Sonnenberg SJ, Frank B (1998) Olanzapine augmentation of clozapine. Ann Clin Psychiatry 10:113-115
15. Hellewell JS (1999) Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry 60 [Suppl 23]:14-19
16. Henderson DC, Goff DC (1996) Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 57:395-397
17. Horacek J (2000) Novel antipsychotics and extrapyramidal side effects. Theory and reality. Pharmacopsychiatry 33 [Suppl 1]:34-42
18. Kaempf P, Agelink MW, Mass R et al. (2003) Amisulpride in addition to clozapine: a retrospective study indicates improved efficacy and good tolerability. Ger J Psychiatry 6:64-68
19. Kapur S, Roy P, Daskalakis J et al. (2001) Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 158:311-314
20. Kaye NS (2003) Ziprasidone augmentation of clozapine in 11 patients. J Clin Psychiatry 64:215-216
21. Kontaxakis VP, Havaki-Kontaxaki BJ, Stamouli SS et al. (2002)Toxic interaction between risperidone and clozapine: a case report. Prog Neuropsychopharmacol Biol Psychiatry 26:407-409
22. Koreen AR, Lieberman JA, Kronig M et al. (1995) Cross-tapering clozapine and risperidone. Am J Psychiatry 152:1690
23. Kraepelin E (1919) Dementia praecox and paraphrenia, 8th edn. Livingstone, Edinburgh
24. Lerner V, Libov I, Kotler M et al. (2004) Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 28:89-98
25. Matthiasson P, Costa DC, Erlandsson K et al. (2000) Increased dopamine D2 receptor binding in the basal ganglia after augmenting clozapine treatment with amisulpride. An 123-I-IBZM SPECT-study. J Psychopharmacol 14 [Suppl 3]:A57
26. Matthiasson P, Erlandsson K, Costa DC et al. (2003) Amisulpride augmentation of clozapine and striatal dopamine d2 receptor binding potential. A 123-I-IBZM study. Schizophr Res 53 [Suppl 3]:208
27. Matthiasson P, Munro JC, Travis MJ et al. (2003) Amisulpride augmentation of clozapine effect in patients with treatment resistant schizophrenia. Schizophr Res 53 [Suppl 3]:209
28. McCarthy RH, Terkelsen KG (1995) Risperidone augmentation of clozapine. Pharmacopsychiatry 28:61-63
29. Meltzer HY (1994) An overview of the mechanism of action of clozapine. J Clin Psychiatry 55 [Suppl B]:47-52
30. Miller DD (2000) Review and management of clozapine side effects. J Clin Psychiatry 61 [Suppl 8]:14-17
31. Morera AL, Barreiro P, Cano-Munoz JL (1999) Risperidone and clozapine combination for the treatment of refractory schizophrenia. Acta Psychiatr Scand 99:305-306
32. Patel JK, Salzman C, Green AI et al. (1997) Chronic schizophrenia: response to clozapine, risperidone, and paroxetine. Am J Psychiatry 154:543-546
33. Prakash C, Kamel A, Anderson W et al. (1997) Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C-and 3H-labeled ziprasidone. Drug Metab Dispos 25:206-218
34. Raskin S, Katz G, Zislin Z et al. (2000) Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiatr Scand 101:334-336
35. Reinstein MJ (1999) Effect of clozapine-quetiapine combination therapy on weight and glycaemic control: preliminary findings. Clin Drug Investig 18:99-104
36. Reinstein MJ (2003) Use of quetiapine to manage patients who experienced adverse effects with clozapine. Clin Drug Investig 23:63-67
37. Rhoads E (2000) Polypharmacy of 2 atypical antipsychotics. J Clin Psychiatry 61:678-680
38. Richelson E (1999) Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 60 [Suppl 10]:5-14
39. Schäfer I, Lambert M, Naber D (2004) Atypical antipsychotics in therapy refractory schizophrenia. Nervenarzt 75:79-91
40. Schumacher JE, Makela EH, Griffin HR (2003) Multiple antipsychotic medication prescribing patterns. Ann Pharmacother 37:951-955
41. Senechal A, Landry P, Deschamps R et al. (2002) Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs. Encephale 28:567-569
42. Sethi KD (2001) Movement disorders induced by dopamine blocking agents. Semin Neurol 21:59-68
43. Shiloh R, Zemishlany Z, Aizenberg D et al. (1997) Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 171:569-573
44. Shiloh R, Zemishlany Z, Aizenberg D et al. (1997) Sulpiride adjunction to clozapine in treatment-resistant schizophrenic patients: a preliminary case series study. Eur Psychiatry 12:152-155
45. Shiovitz TM, Welke TL, Tigel PD et al. (1996) Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr Bull 22:591-595
46. Stahl SM (1999) Antipsychotic polypharmacy, part 2: tips on use and misuse. J Clin Psychiatry 60:506-507
47. Stahl SM (2002) Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr Scand 106:321-322
48. Stahl SM (2002) Antipsychotic polypharmacy: squandering precious recources? J Clin Psychiatry 63:93-94
49. Stephenson CM, Pilowsky LS (1999) Psychopharmacology of olanzapine. A review. Br J Psychiatry [Suppl] 38:52-58
50. Still DJ, Dorson PG, Crismon ML et al. (1996) Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 47:1382-1384
51. Stubbs JH, Haw CM, Staley CJ et al. (2000) Augmentation with sulpiride for a schizophrenic patient partially responsive to clozapine. Acta Psychiatr Scand 102:390-393
52. Taylor CG, Flynn SW, Altman S et al. (2001) An open trial of risperidone augmentation of partial response to clozapine. Schizophr Res 48:155-158
53. Tyson SC, Devane CL, Risch SC (1995) Pharmacokinetic interaction between risperidone and clozapine. Am J Psychiatry 152:1401-1402
54. Wang PS, West JC, Tanielian T et al. (2000) Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull 26:451-457
55. Zink M, Henn FA, Thome J (2004) Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur Psychiatry 19:56-58
56. Zink M, Knopf U, Henn FA et al. (2004) Combination of clozapine and amisulpride in treatment-resistent schizophrenia - case reports and review of the literature. Pharmacopsychiatry 37:26-31
57. Zink M, Mase E, Dressing H (2004) Ziprasidone-augmentation of clozapine. Psychiatr Prax 31:259-261
58. Zink M, Mase E, Dressing H (2004) Combination of ziprasidone and clozapine in treatment-resistant schizophrenia. Hum Psychopharmacol 19:271-273